Simufilam (formerly known as PTI-125) is an investigational drug that represents an entirely new approach to treat Alzheimer’s disease.
Importantly, we do not seek to clear amyloid out of the brain. Our science is based on stabilizing a critical protein in the brain.
Simufilam is a proprietary, small molecule (oral) drug that restores the normal shape and function of altered filamin A (FLNA), a scaffolding protein, in the brain.
The underlying science for simufilam is published in peer-reviewed journals, including Journal of Neuroscience, Neurobiology of Aging, Journal of Biological Chemistry, Neuroimmunology and Neuroinflammation and Journal of Prevention of Alzheimer’s Disease.
We are now in clinical studies to test a new and promising scientific approach for the treatment and diagnosis of Alzheimer's disease. If you are interested in being notified about clinical trials, click here.
Simufilam was developed in-house. Over the years, simufilam has been substantially funded by peer-review research grant awards from the National Institutes of Health (NIH).
Cassava Sciences (NASDAQ:SAVA) says that the company was informed by a medical journal that there was no evidence of data manipulation related to an article that was the basis of the company’s experimental Alzheimer’s drug simufilam.
Simufilam (formerly known as PTI-125) is an investigational drug that
represents an entirely new approach to treat Alzheimer’s disease.
Importantly, we do not seek to clear amyloid out of the brain. Our science
is based on stabilizing a critical protein in the brain.
Simufilam is a proprietary, small molecule (oral) drug that restores the
normal shape and function of altered filamin A (FLNA), a scaffolding protein, in the brain.
The underlying science for simufilam is published in peer-reviewed journals, including Journal of Neuroscience, Neurobiology of Aging, Journal of
Biological Chemistry, Neuroimmunology and Neuroinflammation and Journal of
Prevention of Alzheimer’s Disease.
We are now in clinical studies to test a new and promising scientific
approach for the treatment and diagnosis of Alzheimer's disease. If you are interested in being notified about clinical trials, click here.
Simufilam was developed in-house. Over the years, simufilam has been
substantially funded by peer-review research grant awards from the National Institutes of Health (NIH).
Cassava Sciences (NASDAQ:SAVA) says that the company was informed by a
medical journal that there was no evidence of data manipulation related to
an article that was the basis of the company’s experimental Alzheimer’s
drug simufilam.